Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Microbix Biosystms ( (TSE:MBX) ).
Microbix Biosystems will exhibit at ESCMID Global 2026 in Munich, where it plans to highlight its QAPs quality assessment products and QUANTDx quantified reference materials used to support a wide range of molecular and immunoassay diagnostics. The company aims to engage with current and potential customers at the congress to explore how its controls and reference tools can better support assay development and quality management systems across bacterial, fungal, parasitic, and viral testing.
At the event, Microbix is also presenting research on a new non-infectious phage-encapsulated RNA control designed to provide whole-process quality control for PCR assays targeting RNA viruses such as Hepatitis C. This novel control, which mimics HCV while remaining safe, stable, and reproducible, could help address longstanding gaps in quality management options for blood banks and clinical laboratories dealing with RNA-based pathogens of significant public health concern.
The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Spark’s Take on MBX Stock
According to Spark, TipRanks’ AI Analyst, MBX is a Neutral.
The score is held down primarily by weakened financial performance (return to losses and negative cash flow) and only mildly supportive technicals (negative MACD and below longer-term averages). The earnings call adds some offset from improving sequential trends, cash collections, and operational initiatives, but near-term revenue/margin uncertainty—especially tied to China—keeps the overall score below average.
To see Spark’s full report on MBX stock, click here.
More about Microbix Biosystms
Microbix Biosystems Inc. is a Canadian life sciences company that develops and manufactures proprietary biological products for the global diagnostics industry. Its portfolio includes antigens for immunoassays, quality assessment products (QAPs) and QUANTDx reference materials, which support clinical lab proficiency testing, assay development, validation, and diagnostic workflow quality in more than 30 countries.
The company, which employs over 120 staff and reported C$18.6 million in revenue in fiscal 2025, serves diagnostics makers, accreditation bodies, and clinical laboratories. Microbix also leverages its biological expertise to develop therapeutic and diagnostic-support products, including the Kinlytic urokinase thrombolytic drug and DxTM collection reagents, and operates under multiple international quality and regulatory accreditations while being listed on the TSX and OTCQX exchanges.
Average Trading Volume: 58,244
Technical Sentiment Signal: Sell
Current Market Cap: C$33.25M
See more insights into MBX stock on TipRanks’ Stock Analysis page.